

Supplementary File 4 (data graphed as figure 2 in main manuscript)
Patient Reported Outcome Measures up to 18-months post COVID-19 exposure compared to controls.

Variable	Timepoint	COVID	Controls	Z	P	R
GAD-7	5-months	4.4 ± 4.2	1.6 ± 1.1	-2.70	0.01	-0.32
	12-months	4.2 ± 4.2	2.4 ± 3.4	-1.05	0.29	-0.13
	18-months	2.6 ± 3.5	1.4 ± 1.7	-0.54	0.59	-0.07
PHQ-9	5-months	7.0 ± 4.8	1.1 ± 1.6	-4.14	0	-0.49
	12-months	5.5 ± 5.0	1.5 ± 1.4	-2.92	<0.01	-0.35
	18-months	4.4 ± 4.9	2.1 ± 1.1	-1.07	0.28	-0.15
PCL5	5-months	12.9 ± 13.5	2.2 ± 4.0	-3.27	<0.01	-0.39
	12-months	9.4 ± 14.2	3.6 ± 8.6	-2.05	0.04	-0.25
	18-months	6.6 ± 11.2	2.9 ± 3.6	-0.56	0.58	-0.08
FAS	5-months	23.3 ± 7.5	15.1 ± 2.6	-3.7	<0.01	-0.44
	12-months	21.3 ± 7.8	17.4 ± 7.3	-2.3	0.02	-0.28
	18-months	18.4 ± 6.4	16.4 ± 4.4	-0.80	0.42	-0.11

Generalised anxiety disorder-7 (GAD-7), patient health questionnaire-9 (PHQ-9), patient checklist-5 (PCL-5) for post-traumatic stress, fatigue assessment scale (FAS)